Sentences with phrase «recurrent ovarian»
The study, entitled «Prognostic factors modifying the treatment - free interval in recurrent ovarian cancer,» was supported in part by Roswell Park Comprehensive Cancer Center, a grant from the Roswell Park Alliance Foundation Institute and National Institutes of Health grants P50CA159981 (SPORE award to Roswell Park and the University of Pittsburgh Cancer Institute), P30CA016056, K01LM012100, R01HG007377 and T32CA108456.
https://www.roswellpark.org/
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.
Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum - resistant / refractory, recurrent ovarian cancer.
«Both the efficacy and safety results from the ARIEL3 study reinforce the important role of Rubraca in the treatment of recurrent ovarian cancer and expands the treatment options for patients and physicians battling this disease,» he said.
He concluded: «Once it is approved by the regulatory authorities, I'll consider niraparib for all my patients with recurrent ovarian cancer who respond to platinum regardless of BRCA status.»
The PARP inhibitor niraparib significantly improves the outcome of platinum - sensitive recurrent ovarian cancer, according to full data from the ENGOT - OV16 / NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine (NEJM).
An anti-angiogenic agent, or blood vessel inhibitor, called cediranib (which inhibits a protein known as VEGFR) and olaparib, a PARP inhibitor, are each clinically active in recurrent ovarian cancer.
The ENGOT - OV16 / NOVA trial evaluated the efficacy and safety of the PARP inhibitor niraparib as maintenance therapy in patients with recurrent ovarian cancer who respond to platinum - based chemotherapy.
Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago today.
«Drug combination may be highly effective in recurrent ovarian cancer.»
In 2014, the FDA approved bevacizumab with chemotherapies for the treatment of women with platinum - resistant, recurrent ovarian cancer.
TRINOVA - 1 was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.
«This is an exciting new targeted medication in treating recurrent ovarian cancer.
The products are being studied as treatments for skin cancer, recurrent ovarian cancer and high LDL, or bad cholesterol, that doesn't respond to pills such as Lipitor.
Not exact matches
Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancer.
In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).
The final chapter provides contemporary guidelines for the initial management of ovarian cancer as well as for recurrent disease.
ZEJULA is the first and only once - daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.1 - 3
ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
She is an expert in ovulation induction, in vitro fertilization, egg freezing and egg donation, as well as the management of recurrent pregnancy loss, endometriosis, and polycystic ovarian syndrome.
Thyroid disorders are very common in women with unexplained infertility, premature ovarian failure (a condition in which the number and quality of eggs severely limits fertility), ovulation disorders, and recurrent miscarriage.
We offer effective treatment options for conditions that interfere with fertility: endometriosis, polycystic ovarian syndrome, fibroids, low ovarian reserve, early menopause, autoimmunity, luteal phase defects, hypothyroidisms, recurrent miscarriage, and male infertility.